Investors

Financials

Financial Calendar

January 15, 2026 – Fourth Quarter 2025 Sales

April 15, 2026 – Q1 2026 Sales

April 22, 2026 – 2025 Annual Results

June 4, 2026 – 2026 Annual General Meeting

July 21, 2026 – Q2 2026 Sales

October 8, 2026 – 2026 Half-Year Results

October 20, 2026 – Q3 2026 Sales

Financial Calendar

January 15, 2026 – Fourth Quarter 2025 Sales

April 9, 2026 – 2025 Annual Results

April 16, 2026 – Q1 2026 Sales

June 4, 2026 – 2026 Annual General Meeting

July 21, 2026 – Q2 2026 Sales

October 8, 2026 – 2026 Half-Year Results

October 20, 2026 – Q3 2026 Sales

2024 Annual Financial Report (free translation)

2024 Annual Financial Report (free translation)

Full Year 2024 Sales 

Full Year 2024 Sales 

Mauna Kea Technologies announces the opening of a safeguard proceeding to restructure its financial liabilities 

Mauna Kea Technologies announces the opening of a safeguard proceeding to restructure its financial liabilities 

Full Year 2024 Sales 

Full Year 2024 Sales 

Mauna Kea Technologies Announces its 2025 Financial Calendar

Mauna Kea Technologies Announces its 2025 Financial Calendar

H1 2024 Financial Results and Q3 2024 Sales

H1 2024 Financial Results and Q3 2024 Sales

2023 Annual Financial Report

2023 Annual Financial Report

Full Year 2023 Results and Q1 2024 Sales

Full Year 2023 Results and Q1 2024 Sales

Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank

Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank

Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

Mauna Kea Technologies Reports Full Year 2023 Sales of €10.5m, Up +42% vs 2022

Mauna Kea Technologies Reports Full Year 2023 Sales of €10.5m, Up +42% vs 2022

No results found.

News

Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026 

Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026 

Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 

Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 

Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth 

Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth 

No results found.